Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Up 5.6% in October

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,410,000 shares, an increase of 5.6% from the October 15th total of 3,230,000 shares. Based on an average trading volume of 634,100 shares, the short-interest ratio is currently 5.4 days.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ASND. Stifel Nicolaus lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a report on Friday. StockNews.com lowered shares of Ascendis Pharma A/S from a "hold" rating to a "sell" rating in a research report on Tuesday, November 12th. The Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. decreased their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company upped their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $191.77.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. purchased a new position in Ascendis Pharma A/S during the third quarter valued at approximately $19,908,000. Public Employees Retirement System of Ohio bought a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $1,101,000. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $60,000. Nomura Asset Management Co. Ltd. raised its position in shares of Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock worth $2,688,000 after acquiring an additional 5,371 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth $886,000.

Ascendis Pharma A/S Stock Up 1.8 %

NASDAQ:ASND traded up $2.23 during mid-day trading on Friday, hitting $126.51. 1,448,861 shares of the stock traded hands, compared to its average volume of 368,992. Ascendis Pharma A/S has a 52 week low of $90.13 and a 52 week high of $161.00. The firm's 50 day moving average is $132.30 and its two-hundred day moving average is $132.66. The stock has a market capitalization of $7.67 billion, a price-to-earnings ratio of -15.66 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analysts' expectations of $94.74 million. As a group, research analysts predict that Ascendis Pharma A/S will post -7.3 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.